Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2025 (2025-03-31): -915.72%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$8.04M
Return on Equity (ROE)
-618.74%
TTM Avg
149.09%
3Y Avg
4.64%
5Y Avg
-24.92%
Market Cap
$8.14M
Return on Equity (ROE)
N/A
TTM Avg
-2138.11%
3Y Avg
-1780.63%
5Y Avg
-1152.40%
Market Cap
$7.92M
Return on Equity (ROE)
N/A
TTM Avg
-642.51%
3Y Avg
-382.39%
5Y Avg
-328.67%
Market Cap
$7.87M
Return on Equity (ROE)
-31.99%
TTM Avg
-84.19%
3Y Avg
-171.49%
5Y Avg
-138.23%
Market Cap
$8.33M
Return on Equity (ROE)
-34.67%
TTM Avg
10.89%
3Y Avg
102.13%
5Y Avg
71.00%
Market Cap
$7.75M
Return on Equity (ROE)
-91.75%
TTM Avg
-295.51%
3Y Avg
-88.38%
5Y Avg
-106.70%
Market Cap
$7.67M
Return on Equity (ROE)
-93.77%
TTM Avg
-380.19%
3Y Avg
-280.27%
5Y Avg
-231.46%
Market Cap
$7.64M
Return on Equity (ROE)
-120.58%
TTM Avg
-99.12%
3Y Avg
-428.18%
5Y Avg
-321.37%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DataMEDS AI, Inc. (MEDS) | $8.05M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $8.04M | -618.74% | 149.09% | 4.64% | -24.92% |
| HeartSciences Inc. (HSCS)vs › | $8.14M | N/A | -2138.11% | -1780.63% | -1152.40% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | N/A | -642.51% | -382.39% | -328.67% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.87M | -31.99% | -84.19% | -171.49% | -138.23% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | -34.67% | 10.89% | 102.13% | 71.00% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | -91.75% | -295.51% | -88.38% | -106.70% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.67M | -93.77% | -380.19% | -280.27% | -231.46% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.64M | -120.58% | -99.12% | -428.18% | -321.37% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.46M | -85.24% | 23.31% | -10.41% | -27.01% |
ROE
N/A
ROA
-269.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | -915.72% |
| 2024-12-31 | -153.79% |
| 2024-09-30 | -178.49% |
